Biodesix (BDSX) Q3 2023: Lung Test Volumes Surge 60%, Margin Leverage Accelerates Path to Profitability
Biodesix’s Q3 marked a decisive step toward profitability, with lung test volumes up 60% and gross margin reaching 76% as the company leverages Medicare-backed diagnostics and biopharma partnerships. Management is doubling down on targeted salesforce expansion and clinical evidence, while cash discipline and operational leverage are sharpening the company’s financial profile. The guidance reset, tied to Medicare Advantage payment delays, leaves core business momentum intact and sets the stage for continued high-growth execution into 2024.
Summary
- Lung Test Adoption Momentum: Salesforce expansion and clinical data drive robust volume growth and market presence.
- Margin Expansion Signals Operating Leverage: Gross margin improvement reflects test mix shift and workflow optimization.
- Guidance Reset Is Payment Timing, Not Demand: Medicare Advantage backlog removal does not alter core growth trajectory.
Business Overview
Biodesix is a diagnostics company focused on blood-based precision tests for lung cancer care, spanning early nodule risk assessment to post-diagnosis treatment guidance. The company’s commercial portfolio, which includes Notify CDT, Notify XL2, Veristrat, and Genistrat tests, generates revenue through test sales to healthcare providers and biopharma partners. Its two main segments are lung diagnostic testing, the core driver, and biopharmaceutical services, which supports clinical trials and research collaborations. All five lung tests are covered by Medicare, anchoring payer access and reimbursement stability.
Performance Analysis
Biodesix delivered a standout quarter, with total revenue up sharply year-over-year, propelled by lung diagnostic revenue growth and a significant rebound in biopharma services. The core lung diagnostics segment contributed the vast majority of revenue, with test volumes up 60% to 10,400, marking the fifth consecutive quarter of at least 60% year-on-year growth. This acceleration is driven by continued Notify XL2 adoption and deeper commercial penetration.
Gross margin expanded to 76%, reflecting a favorable mix toward higher-margin lung tests and successful workflow optimization, while COVID testing wind-down further improved profitability. Operating expenses declined sequentially and year-over-year as management prioritized near-term revenue projects and delayed longer-term initiatives, resulting in a 40% improvement in adjusted EBITDA loss versus the prior quarter. The biopharma services business rebounded with 79% growth, and contracted but unrecognized revenue rose to $9.9 million, underscoring future visibility.
- Lung Diagnostics Dominance: The segment accounted for over 90% of total revenue, fueled by Medicare-backed test adoption and robust salesforce productivity.
- Biopharma Services Upswing: Revenue nearly doubled year-over-year, with a growing backlog indicating sustained partner demand.
- Cost Structure Discipline: Lower R&D and project prioritization drove sequential and annual OPEX reduction, amplifying margin leverage.
Cash and liquidity improved with a private placement and facility investments, positioning Biodesix to support further commercial and operational scaling. The company’s guidance revision stems from Medicare Advantage payment delays, not underlying demand, keeping the growth narrative intact.
Executive Commentary
"We grew lung diagnostic test volumes and revenue, saw a healthy rebound in our biopharmaceutical partnerships and services business, expanded our gross margins to the mid-70s, and did so while reducing operating expense. Clearly, our commitment to a cost-disciplined approach while growing and expanding the business continues to pay off, and I believe everyone is beginning to appreciate the leverage that exists within the business model and our efforts to demonstrate the team's significant progress and outstanding execution on our path to profitability."
Scott Hutton, Chief Executive Officer
"The improvement in adjusted EBITDA in the quarter demonstrates our focus on actively managing our operating expenses, our success in improving gross margins, and driving growth in the top line revenue. We ended the quarter with $19.8 million in unrestricted cash and cash equivalents... In the fourth quarter, the company will receive the remaining $12.2 million from the private placement and also plans to draw down an additional $10 million from Tranche B of its $50 million term loan facility."
Robin Harper-Cowie, Chief Financial Officer
Strategic Positioning
1. Salesforce Expansion and Productivity
Biodesix is methodically scaling its salesforce, keeping territories lean to maximize rep productivity and minimize travel costs. New hires are ramping to full productivity in two to three months, a marked improvement from prior periods. Leadership sees no evidence of sales rep productivity plateauing, indicating continued organic growth potential as the team expands.
2. Clinical Evidence and Reimbursement Leverage
Clinical data generation is central to Biodesix’s strategy, with multiple studies (Oracle, Insight, AABIP, CHEST) reinforcing the utility of Notify XL2 and Veristrat. Notably, the Oracle study showed a 74% reduction in unnecessary invasive procedures. ADLT (Advanced Diagnostic Laboratory Test) status for three tests, including Notify CDT, strengthens Medicare reimbursement and differentiates the portfolio.
3. Biopharma Partnerships and Contracted Backlog
Biopharma services revenue rebounded strongly, and the $9.9 million in contracted but unrecognized revenue highlights a growing pipeline of clinical trial support work. This segment provides diversification and embedded future revenue as projects progress.
4. Operational Leverage and Facility Investment
Gross margin expansion and OPEX control underscore operational leverage, with workflow optimization and COVID exit effects supporting profitability. The move to a new, energy-efficient facility in Colorado will further enhance testing capacity, kit manufacturing, and ESG positioning.
5. Product Pipeline and Commercial Focus
Development of the risk of recurrence test is deprioritized in favor of maximizing Notify franchise momentum. Management is focused on near-term returns, with additional private payer coverage for Notify CDT expected to incrementally lift ASPs over time.
Key Considerations
This quarter signals a turning point in Biodesix’s ability to scale profitably, with salesforce leverage, margin expansion, and biopharma diversification all contributing to a more robust business model. Investors should weigh the following:
Key Considerations:
- Salesforce Ramp Drives Growth: Lean territory management and rapid rep ramping underpin sustained test volume acceleration.
- Reimbursement Foundation Is Durable: Medicare and ADLT status anchor pricing and access, with private payer wins as upside.
- Clinical Data Underpins Adoption: Real-world studies and conference presentations continue to validate test utility for providers and payers.
- Biopharma Services Provide Revenue Visibility: Growing backlog and partner engagement hedge against core diagnostics cyclicality.
- Cash Position and Facility Investment: Recent financing and new facility support future growth and operational scale.
Risks
Medicare Advantage payment delays, while not reflective of core demand, introduce near-term revenue recognition uncertainty and highlight broader healthcare reimbursement friction. Commercial execution risk remains as Biodesix continues to scale its salesforce and integrate new hires. Guideline inclusion timing is unpredictable, and any stalling of clinical adoption or reimbursement expansion could temper growth. Biopharma services revenue is inherently lumpy and project-dependent, while competitive innovation in lung diagnostics is an ongoing threat.
Forward Outlook
For Q4 2023, Biodesix guided to:
- Total revenue of $50 to $52 million for the full year, with the spread reflecting the timing of Medicare Advantage collections.
For full-year 2023, management maintained core growth expectations, excluding the $2.5 to $3 million Medicare Advantage backlog.
- Continued strong lung diagnostics growth and modest biopharma services expansion underpin the outlook.
Management emphasized that guidance reflects operational momentum and reimbursement progress, with the only change tied to collection timing, not underlying business health.
- Salesforce expansion will continue at a measured pace, with six new hires per quarter targeted.
- Private payer coverage and additional clinical data releases remain on the near-term roadmap.
Takeaways
Biodesix’s Q3 results reinforce a business model gaining operational and financial leverage, with lung diagnostics demand, margin expansion, and disciplined execution at the forefront. The guidance reset is a function of payment timing, not demand, and does not detract from the underlying growth story.
- Volume and Margin Leverage: Five straight quarters of 60%+ test volume growth and 76% gross margin demonstrate strong demand and operational efficiency.
- Salesforce and Clinical Strategy: Targeted salesforce expansion and robust clinical data are key to sustaining adoption and payer coverage momentum.
- 2024 Watchpoint: Monitor private payer wins, biopharma backlog conversion, and productivity of new sales hires as leading indicators of continued scale and profitability progress.
Conclusion
Biodesix is executing a disciplined growth strategy, with test adoption, margin leverage, and cash discipline converging to accelerate its path to profitability. With a robust reimbursement foundation and expanding commercial reach, the company is well-positioned to capitalize on the large and underserved lung cancer diagnostics market.
Industry Read-Through
Biodesix’s performance and commentary signal several broader diagnostics sector trends: Clinical utility data and payer coverage are increasingly critical to commercial success, especially as Medicare and ADLT status become differentiators. Salesforce productivity and operational leverage are emerging as key value drivers, separating scale-ready platforms from those reliant on heavy R&D spend. Biopharma services diversification is a growing theme, providing diagnostics companies with revenue stability and strategic partnerships. Finally, Medicare Advantage payment friction is a sector-wide issue, likely to impact other diagnostics and healthcare services firms reliant on government-backed plans for revenue recognition.